Lexaria Bioscience Corp Ordinary Shares LEXX 深 沪
等待开盘 09-10 09:30:00 美东时间
0.9998
-0.040
-3.87%
华盛通- 最 高1.06
- 今 开1.05
- 成交量 15.61万股
- 最 低 0.99
- 昨 收 1.04
- 总市值 1955.53万
- 52周最高 3.3915
- 市盈率 静 --
- 换手率 0.80%
- 52周最低 0.7749
- 委 比 98.07%
- 总股本 1955.92万
- 历史最高 12.50
- 量 比 1.27
- 振 幅 6.73%
- 历史最低 0.6488
- 每 手 1
- 风险率 0.76%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexaria Bioscience's Contract Research Organization Completes Last Patent Last Visit Study Milestone In Lexaria's Phase 1b Glucagon-Like Peptide-1 Study In Australia, GLP-1-H24-4
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that its Contract Research Organization ("CRO") has completed the
08-14 21:23
Lexaria Bioscience Targets GLP-1 Market with DehydraTECH Innovation
Lexaria Bioscience ( ($LEXX) ) has shared an update. Lexaria Bioscience is posi...
08-06 22:42
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation
https://s27.q4cdn.com/906368049/files/News/2025/Zacks_SCR_Research_07312025_LEXX_Vandermosten.pdf
07-31 22:58
Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lexicon Pharmaceuticals announced that its common stock has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its closing bid price met the $1.00 per share requirement for ten consecutive business days. This update was previously disclosed in the Company’s Form 8-K filed on July 28, 2025. Lexicon, a biopharmaceutical company, focuses on pioneering innovative medicines through its Genome5000™ program, targeting diseases like heart fail...
07-31 12:00
Lexaria’s DehydraTECH Technology Poised to Transform GLP-1 Industry
Lexaria Bioscience ( ($LEXX) ) just unveiled an announcement. Lexaria Bioscienc...
07-23 23:09
Lexaria's DehydraTECH Targets Side Effects In GLP-1 Market, Offers Relief For Semaglutide, Tirzepatide, And Liraglutide Users
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:29
Lexaria Bioscience Prpvides Strategic Update Of Glucagon-Like Peptide-1
The fastest growing sector in the global pharmaceutical industry is struggling to face its most serious challenge: unwanted side effectsDehydraTECH reduces side effects and could support patient retention and further
07-23 21:28
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DIH Holding US (NASDAQ:DHAI) shares rose 35.1% to $0.34 during Friday'...
07-19 05:06
Lexaria Bioscience Q3 EPS $(0.21) Misses $(0.16) Estimate, Sales $174.000K Beat $91.333K Estimate
Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.16) by 33.76 percent. This is a 61.54 percent decrease over losses of $(0.13) per share
07-15 06:32
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
